



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Bertilimumab

<b>Cat. No.:</b>	HY-P99474
<b>CAS No.:</b>	375348-49-5
<b>Target:</b>	CCR
<b>Pathway:</b>	GPCR/G Protein; Immunology/Inflammation
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research <sup>[1]</sup> .	
<b>In Vitro</b>	Bertilimumab (CAT 213) neutralizes the ability of eotaxin-1 to cause an increase in intracellular calcium signaling (with an IC <sub>50</sub> value of 2.86 nM), migration of CCR3-expressing L1.2 cells (with an IC <sub>50</sub> value of 0.48 nM), and inhibition of the eotaxin1-evoked shape change of human eosinophils in vitro (with an IC <sub>50</sub> of 0.71 nM) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	Bertilimumab (CAT 213) (0.01-10 mg/kg) administered i.v. 30 min before i.po. injection of human eotaxin1 (1 µg) causes a significant dose-dependent inhibition of eosinophil recruitment in IL-5-treated, ovalbumin-sensitized mice. Bertilimumab also significantly inhibits neutrophil and mononuclear cell influx into the air pouch, which resulted in a dose-related inhibition of total cell influx <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	<b>Animal Model:</b>	Female BALB/c mice (17-21 g) injected human eotaxin1 <sup>[1]</sup> .
	<b>Dosage:</b>	0.01 mg/kg, 0.1 mg/kg, 1 mg/kg, 10 mg/kg
	<b>Administration:</b>	i.v.; once
	<b>Result:</b>	Caused a significant dose-dependent inhibition of eosinophil recruitment in IL-5-treated, ovalbumin-sensitized mice.

### REFERENCES

[1]. Sarah Main, et al. A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy. J Pharmacol Exp Ther. 2006 Dec;319(3):1395-404.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA